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Autologous serum has been used to treat dry eye syndrome for many years.
It contains several growth factors, vitamins, fibronectin and other com-
ponents that have been considered important for corneal and conjunctival
integrity. Serum eye drops are usually prepared as an unpreserved blood
solution. The serum is by nature well tolerated and its biochemical
properties are somewhat similar to natural tears. Autologous serum eye
drops have been reported to be effective for the treatment of severe dry
eye-related ocular surface disorders (Sjögren’s syndrome), and also other
entities such as superior limbic keratoconjunctivitis, graft-versus-host
disease, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, re-
current or persistent corneal erosions, neurotrophic keratopathy, Mooren’s
ulcer, aniridic keratopathy, filtering blebs after trabeculectomy, and post-
keratorefractive surgery. The purpose of this study is to review the recently
published literature on ocular surface diseases treated with human
autologous serum eye drops.
ABSTRACT
INTRODUCTION
The ecosystem of the ocular surface depends on the dynamic interac-
tions of healthy adnexa (eyelid margins), adequate blink rate, normal tear
production, and ocular surface tissue, consisting of cornea and conjunc-
tiva(1). Tears have a significant importance in the stability of the corneal
and conjunctival epithelia due to the interdependence between the va-
rious structures comprising the ocular surface. The corneal demand for
glucose, electrolytes, and amino acids is supplied by the aqueous humor,
and growth factors, vitamins and neuropeptides secreted by lacrimal
glands, which support proliferation, migration, and differentiation of the
ocular surface epithelia. Tears have lubricating and mechanical proper-
ties, but also epitheliotrophic and antimicrobial effects. A reduction of
epitheliotrophic factors compromises the integrity of the surface epithelia.
This can lead to epithelial defects that tend to persist and progress as a result
of the compromised wound healing process(2).
Conventional therapeutic options include intensive artificial tear
supplements, punctal occlusion, contact lenses, and appropriate manage-
ment of adnexal disease. The most frequent therapy utilized to treat ocular
surface disorders is artificial tear eye drops. However, none of the com-
mercially available artificial tear preparations includes essential tear com-
ponents such as growth factors, vitamins, and immunoglobulins. Another
drawback of artificial tears is the fact that they often contain preservatives,
stabilizers, and other additives, which potentially induce toxic or allergic
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reactions(3). Despite maximal conventional therapy, there is a
cohort of patients who still have persistent symptoms and
signs. Such patients may have more serious ocular surface
disorders with significant visual impairment and disability.
Autologous serum eye drops have been recommended for
the treatment of several ocular surface disturbances, such as
Sjögren’s syndrome-related tear deficiency, non-Sjögren’s tear
deficiency associated with graft-versus-host disease, neurotro-
phic keratitis, persistent epithelial defects, superior limbic
keratoconjunctivitis, as well as a supportive measure in ocular
surface reconstruction(4). Its utilization in Ophthalmology
arose out of the need of finding lacrimal substitutes which, in
addition to lubricating the ocular surface, were able to provide
other components of tears that are reduced in ocular surface
disease(5). Human serum contains substances such as epidermal
growth factor, vitamin A, transforming growth factor-β, fibro-
nectin, and cytokines normally found in tears. These factors
are important for maintaining a healthy corneal and conjunc-
tival epithelium(4). This review summarizes the recently publi-
shed literature on the ocular surface diseases treated with auto-
logous serum.
First trials
The rationale for the topical use of autologous serum is
based on the premise that chemotactic and growth factors
present in tears are also present in patient’s own serum. Mo-
reover, the biochemical properties of the serum are similar to
that of normal tears. Fox et al.(6) initially described the bene-
fits of autologous serum application in dry eyes in patients
with Sjögren’s syndrome. However, the lack of knowledge
about its mechanism of action at the ocular surface level kept
its utilization in clinical practice from growing until the end
of the decade, when Tsubota et al.(7) evaluated the efficacy of
autologous serum drops diluted with saline in the treatment
of 12 patients with Sjögren’s syndrome. The authors used the
parameters of fluorescein and rose bengal staining, tear
break-up time, and subjective symptomatic scores to assess
efficacy. Improvement occurred in all parameters, which were
measured at the second and fourth week after autologous
serum eye drop application. The main drawback of this study
was related to its non-comparative nature, where the patients
used autologous serum in addition to artificial tears.
Human serum properties
It is known that autologous serum contains some compo-
nents involved in the proliferation, migration and differen-
tiation of the ocular surface epithelial cells. It is believed that
many serum components may have some trophic effects on
the surface epithelial cells due to their action on epithelial
dynamics, modeling the proliferation of epithelial cells in
the limbus and cornea(1). In vitro studies with conjunctival
epithelial cells have proved an effect of autologous serum on
the expression of mucins, mainly MUC1, regulated by EGF
receptors in the cup shaped cells(7). The effect of autologous
serum on the ocular surface is determined by its numerous
properties. Serum exhibits characteristics which are very
similar to those of tears regarding pH and osmolarity. Like
tears, it contains abundant growth factors and bactericidal
components, which provide the nutritional factors necessary
to maintain cellular viability in the epithelial repair processes,
and bactericidal components to reduce the risk of contamina-
tion and infection(8). Autologous serum therapy produces a
temporary beneficial effect on the epithelial surface which
disappears when its application is interrupted(7). The efficacy
of this treatment in persistent epithelial defects begins to be
noticed at the second week of follow-up, although a subjective
improvement of patients begins about the second day of treat-
ment(9).
Of all human serum components, it is believed that the
most important for ocular surface are: epithelial growth factor
(EGF), transformer growth fibroblast β-factor (TGF-β), vita-
min A, fibronectin, albumin, α-2 macroglobulin, the plate-
let-derived growth factor (PDGF-AB), hepatocyte growth
factor, neuropeptides such as substance P and the insulin-
like growth factor. Accordingly, EGF accelerates the migra-
tion process of epithelial cells, and has anti-apoptotic ef-
fects. This factor is present in the basal as well as reflex
lacrimal secretion, with a slightly lower concentration to the
one it has in autologous serum. TGF-β is involved in epithe-
lial and stromal repair processes, with its concentration in
serum being three times more than the concentration found in
tears. Vitamin A seems to prevent squamous metaplasia pro-
cesses of epithelium. Its concentration in serum is much
higher to that found in tears. On the other hand, proteins such
as albumin have proved to have anti-apoptotic activity, while
α-2 macroglobulin exhibits anti-collagenase activity. Fibro-
nectin is one of the most important factors in cellular migra-
tion, with its concentration in serum being significantly abo-
ve that found in tears.
Autologous serum contains neuronal factors such as
substance P and insulin-1-type growth factor, which seem to
play a role in the migration and adhesion of the corneal epithe-
lium to its stroma. PDGF-AB is one of the 5 known isoforms of
platelet-derivated growth factors and is activated intracellu-
larly and secreted by the alpha granules of platelets after its
activation, enhancing mitosis and scarring. In addition, auto-
logous serum contains immunoglobulines such as IgG, IgA,
lysozyme and supplemental factors that provide bactericide
and bacteriostatic effects(5). Table 1 shows the comparative
relationship between concentrations of the main epitheliotro-
phic factors found in tears and in autologous serum.
Preparation of serum and patient
There is a large variability in the preparation methodo-
logy, storage and dispensation of autologous serum eye
drops. In addition, most authors agree on the need for stan-
dard criteria by means of multicentric randomized studies to
optimize the results obtained with this treatment(5). Blood is
extracted from patient’s vein with vacuum extraction tubes
without anticoagulant. Subsequently, the tubes are left in
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vertical position at 22°C for about 2 hours to allow coagula-
tion. After blood clot is formed, supernatant is centrifuged to
separate the serum from the solid components. A bottle of
serum eye drops with the desired concentration, adequately
identified and preserved from light is given to the patient. It
is important to keep the eye drops away from light because
some of its components (vitamin A) degrade quickly with
light exposure. Most prepared all the autologous serum eye
drops with fresh serum, giving the flasks to the patients for
their utilization, recommending them to keep the one in use
in the refrigerator at +4°C(5). Regarding dispensation, some
authors suggest a flask per day while others the same flask for
one week(2,5). The remaining bottles should be stored frozen
(ideally at -20°C) for up to 3 months(2). The number of appli-
cations varies from once every hour up to 3 times a day. Some
authors believe that concentrations of 50% or 100% would
have more effect on the eye surface(1,9). However, the most
standardized dilution of autologous serum is at 20% which is
based on the concentration of certain growth factors in
tears(2,7). It also seems to avoid the irritation derived from the
higher viscosity in concentrated preparations and may act
favorably by reducing the number of blood extraction proce-
dures(4). Table 2 describes the variation in storage, prepara-
tion and application published in the literature.
Indications
Autologous serum has been utilized with varying success
for managing numerous processes involving the corneal
surface. Its successful application has been reported in the
treatment of the following entities:
Severe dry eye
Dry eye syndrome is recognized as a growing public
health problem and one of the most frequent reasons for
seeking eye care. The estimated prevalence for people ≥ 50
year-old in the United States is 7.8% for women (approxima-
tely 3.2 million affected), and 4.7% for men (approximately
1.6 million affected)(10). Dry eye syndrome is characterized
by a deficiency in the quality or quantity of tears, an unstable
tear film, ocular surface damage, and bothersome symptoms
such as ocular irritation, grittiness, fatigue, and fluctuating
vision(11-12).
Tananuvat et al.(13) conducted a prospective, single-mas-
ked, placebo-controlled study in 12 patients with bilateral
severe dry eye. One eye was randomized to receive 20% auto-
logous serum as a tear substitute, and the fellow eye received
unpreserved normal saline solution. There was a trend toward
improvement in symptoms and signs of dry eye including
favorable impression cytology changes in the autologous
serum group, but this trend was not statistically significant.
Noble et al.(1) evaluated the efficacy of 50% autologous
serum drops in Sjögren’s syndrome (6 patients) and kerato-
conjunctivitis sicca (5 patients) in a prospective randomized
crossover trial. Impression cytology showed significant im-
provement in the autologous serum (P<0.01), but no differen-
ce was found in either rose bengal staining, Schirmer test, or
tear clearance test. The crossover design of the study confir-
med that these improvements were due to autologous serum
drops, and that the beneficial effects were probably due to the
presence of essential tear factors in the serum. For most of
these patients, autologous serum was superior to conventio-
nal treatment for improving ocular surface health and subjec-
tive comfort.
Kojima et al.(14) have evaluated the effectiveness of the
20% autologous serum eye drops in the treatment of severe dry
eye patients. Thirty seven eyes (20 severe dry eye patients)
without punctal occlusion were prospectively randomized in a
case-control study. Group A patients used preservative-free
artificial tears, and group S patients used autologous serum
drops. The mean break-up time and fluorescein and rose
bengal staining scores, as well as subjective symptoms scores,
showed significant improvement in the patients assigned to
autologous serum eye drops compared with subjects assigned
to preservative-free artificial tears after 2 weeks of treatment.
Based on these findings, autologous serum was found to be
superior to conventional treatment with artificial tears for
improving ocular surface health and subjective comfort.
Hyon et al.(15) assessed the clinical efficacy of anti-inflam-
matory therapy in the management of primary Sjögren’s syn-
drome in 38 patients. Anti-inflammatory therapy included
Table 1. Comparison of the biochemical properties of normal
human tears and serum(2,5)
Tears Serum
pH 7.4 7.4
Osmolarity 298 296
EGF (ng/ml) 0.2-3.0 0.5
TGF-β (ng/ml) 2-10 6-33
Vitamin A (mg/ml) 0.02 46
Lysozyme (mg/ml) 1.4 6
IgA (μg/ml) 1190 2
Fibronectin (μg/ml) 21 205
EGF= epithelial growth factor; TGF= transforming growth factor
Table 2. Previously described variations, storage, and applica-
tion of serum eye drops(2)
Production factor Published variations
Clotting phase 0-2 days
Centrifugal force 1500 rpm (300 g) to
4000 g (5000 rpm)
Duration of centrifugation 5-20 minutes
Dilution 20%, 33%, 50%, or 100%
Diluent 0.9% NaCl, BSS, 0.5%
chloramphenicol eye drops
Container 1-6 ml in insulin
syringe or dropper bottle
Storage -20° to +4°C
Number of daily applications 3 times to hourly
rpm= round per minute; g= g force; BSS= balanced salt solution
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topical corticosteroid, 20% topical autologous serum, and
topical cyclosporine A. Subjective symptoms improved with
anti-inflammatory treatment in 70% of patients with primary
Sjögren’s syndrome. Associated anti-inflammatory treatment
provided significant improvement in visual acuity and fluo-
rescein score but did not affect Schirmer score, tear break-up
time, or rose bengal score. However, the authors did not find
evidence that anti-inflammatory treatment increases tear pro-
duction in patients with Sjögren’s syndrome.
Recently, in 2008, Lee and Chen(16) evaluated the efficacy
and safety of long-term application of 20% autologous serum
eye drops to treat recalcitrant dry eye syndrome. This is a
retrospective chart review of 46 eyes of 23 patients in a follow-
up period of 17.3 months (range 6 to 55 months). Corneal
fluorescein staining of 34 eyes (73.9%) showed improvement.
Eighteen patients (35 eyes, 76.1%) reported subjective impro-
vement after using autologous serum eye drops. No significant
complications were reported in this study.
Persistent epithelial corneal defect
Severe dry eye and neurotrophic ulcers present the most
severe types of persistent epithelial defect (PED). Desic-
cation itself can be compensated by the frequent use of pre-
servative-free artificial tears combined with the use of mois-
ture chamber glasses, punctal plugs, or both. However, the
lack of tear production results in the deprivation of essential
tear components such as epidermal growth factor and vitamin
A to the ocular surface epithelium(17).
Tsubota et al.(17) have shown the efficacy of autologous
serum application for the treatment of PED. A non-comparati-
ve case series of 16 eyes was assessed prospectively. Autolo-
gous serum was prepared and diluted to 20% in saline, with a
dosage of 6 to 10 times daily. Among all eyes with PED, 7
(43.8%) healed within 2 weeks, 3 (18.8%) healed within 1
month, and the remaining 6 (37.5%) did not respond within 1
month. In summary, autologous serum application was effec-
tive in more than 60% of the cases of PED.
Young et al.(18) studied retrospectively 10 eyes of 10 pa-
tients with PED treated with 20% autologous serum eye
drops. The mean duration of PED before the treatment was
22.4 days. Six eyes healed within 2 weeks, but 2 eyes failed to
heal after 1 month of treatment and 2 patients were lost from
follow-up.
Alvarado Valero et al.(19) studied the impact of topical
treatment with 20% autologous serum on the clinical evolu-
tion of PED. In this prospective case series study of 17 eyes of
14 patients, the epithelial defect healed within 2 weeks in 6
eyes (35.3%). Eight eyes (47%) healed within 2 to 4 weeks
and 3 eyes (17.6%) did not heal after week 4. The duration of
PED, before serum therapy was 36 days. Six of 7 treated eyes
presented an involution of squamous metaplasia 28 days
after initiation of the autologous serum drops.
Schader et al.(20) reported 6 eyes of 5 patients with PED
which were treated with 20% autologous serum eye drops in
combination with bandage contact lenses (BCL). All patients
had been unsuccessfully treated with conventional therapy
before. The PED healed in 5 of 6 eyes after a treatment period
of 14.2 ± 8.9 days. In 1 eye the PED became smaller, but took
90 days until the lesion healed completely. These findings
suggest that the combination of a BCL and autologous serum
eye drops can be successfully used in the treatment of PED.
Deposition of albumin may occur on the surface of the con-
tact lenses, which, in the small group presented in this study,
caused no unwanted effects.
Recurrent corneal erosion
Corneal erosions can be an extremely painful condition
for many patients. The pathogenic mechanism is linked to
abnormalities of the adhesion complex between the corneal
epithelium and the stromal layer. The etiologies for erosions
are very wide and include trauma, dry eye, corneal dystro-
phies, and eyelid diseases that occur after infection or spon-
taneously(21). Holzer et al.(22) evaluated the clinical outcomes
after transepithelial phototherapeutic keratectomy (t-PTK)
using an excimer laser and postoperative administration of
20% autologous serum eye drops to treat 25 eyes of 25
patients with 3 to 12 recurrent erosions. Postoperatively,
autologous serum eye drops were administrated 6 times a day
for 6 weeks. Twenty eyes (80%) recovered without further
corneal erosion in a follow-up period of 15.5 months (range 6
to 20 months). Five eyes had 1 further erosion, which was
treated in 4 cases with autologous serum without additional
excimer laser treatment. One patient requested additional t-
PTK treatment and recovered without further complications
thereafter.
Del Castillo et al.(23) studied the effect of 20% autologous
serum in the treatment of recurrent corneal erosions in 11
eyes of 11 patients. Mean follow-up time was 9.4 ± 3.7 mon-
ths (range, 4 to 16). Treatments prior to the use of autologous
serum had failed to avoid recurrences in all patients, with the
mean recurrence rate being 2.2 recurrences per month of
follow-up. After the onset of serum treatment, only a single
recurrence was recorded in 3 of the patients. Thus, the use of
autologous serum for the treatment of patients with recurrent
corneal erosion appears to be effective and safe in reducing
the number of recurrences experienced by patients.
Neurotrophic keratopathy
Numerous ocular and systemic diseases, including viral
keratitis, chemical or thermal burns of the ocular surface, fifth
nerve palsy after removal of acoustic neuroma or radiation,
drug toxicity, corneal surgery, multiple sclerosis, and diabe-
tes, may lead to neurotrophic keratopathy (NK). This presents
with a broad spectrum of corneal findings, including superfi-
cial punctate keratitis, epithelial defects, ulceration, and per-
foration. In neurotrophic ulcers, neural factors such as acetyl-
choline or substance P are depleted from the cornea. Nishida
et al.(24) emphasized the importance of substance P and insu-
lin-like growth factor for a normal wound-healing response.
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Matsumoto et al.(25) reported the treatment of 14 eyes of 11
patients with NK with application of 20% autologous serum
eye drops 5 to 10 times daily until the defect healed. The
epithelial defect healed completely in all eyes within 6 to 32
days (mean, 17.1 ± 8.0 days), with a decrease in corneal
scarring. Corneal sensitivity, as measured by Cochet-Bonnet
esthesiometer, increased from a pretreatment level of 11.8 mm
to 30.0 mm after treatment at the last follow-up, and 5 eyes
achieved normal corneal sensitivity with treatment. Moreo-
ver, the authors demonstrated that the best-corrected visual
acuity improved in 78.6% of the eyes with treatment. Signi-
ficantly increased concentrations of nerve growth factor,
insulin-like growth factor, and substance P were noted in the
serum tears that were not found in the patient’s normal tear
samples. It was concluded that autologous serum harbors
neurotrophic factors and may provide neurologic healers for
a compromised ocular surface.
Filtering blebs after trabeculectomy
Aqueous leakage from filtering blebs is not a rare condition
after trabeculectomy with antimetabolites, which can pose a
potential risk for bleb-related complication. Although the
effects of serum on the conjunctiva have not been fully stu-
died, vitamin A and epidermal growth factor are reported to
have roles in maintaining the normal histology in the conjunc-
tiva. Matsuo et al.(26) evaluated the efficacy of 20% topical
autologous serum application to stop aqueous oozing or
point-leak through filtering bleb after trabeculectomy. A total
of 21 eyes with oozing and 21 eyes with a point-leak through a
functional bleb after trabeculectomy with 5-fluoracil or mito-
mycin C were enrolled in this randomized case-control study.
The serum was topically applied 4 times a day for up to 12
weeks. In the serum and control groups, oozing stopped in
62.5% and 0% of eyes, respectively (P=0.003), and point-leaks
stopped in 27.3 and 18.2%, respectively (P>0.9). These fin-
dings suggest that autologous serum application was signifi-
cantly effective to stop aqueous oozing but not point-leaks.
Superior limbic keratoconjunctivitis
Superior limbic keratoconjunctivitis (SLK) is a relatively
uncommon ocular surface disorder, and mild clinical findings
can cause a significant patient discomfort. Fine punctate rose
bengal and fluorescein staining of the superior cornea and
limbus are sometimes the only clinical signs detected. Its etio-
logy is not completely understood, and various causes, such as
eye rubbing, viral infection, and autoimmune diseases have
been proposed, as well as a diverse range of possible treat-
ments. Goto et al.(27) assessed the efficacy of autologous serum
drops in the treatment of SLK. Twenty two eyes of 11 SLK
patients were treated with 20% autologous serum 10 times a
day in addition to ongoing treatment of dry eye. Previous
therapies, including artificial tears, topical corticosteroids,
and topical vitamin A, were ineffective. Nine of the 11 patients
reported subjective improvement (81.8%), and all eyes
showed objective improvement (100%) by rose bengal or
fluorescein staining. Despite the good results obtained in this
study, the authors proposed that punctal occlusion be consi-
dered the first choice of therapy for SLK, and if conventional
treatment is ineffective, autologous serum drops should be
added to the regime.
Graft-versus-host disease
Allogeneic haematopoietic stem cell transplantation
(SCT) is considered a curative treatment for various hemato-
logical malignancies. However, chronic graft-versus-host di-
sease (GVHD) remains a major complication after SCT, and is
the largest factor in impairing the quality of life of transplant
recipients. Dry eye is one of the major symptoms of GVHD.
Although several therapies have been used to minimize the
symptoms of dry eyes associated with GVHD, an effective
treatment has not been established. In 2000, Rocha et al.(28)
reported the first two cases of GVHD with severe dry eyes
treated with autologous serum, which proved to be safe during
the 10 months of treatment. Ogawa et al.(29), in 2003, utilized
autologous serum eye drops to treat 14 patients with severe dry
eye associated with GVHD. The patients had been refractory to
treatment with conventional artificial tears. A 20% solution of
serum and sterile saline was applied 10 times a day. Mean
follow-up was 19.4 months (range 4 to 41 months). After 4
weeks of treatment, significant improvement was observed in
both complaint scores (P<0.01) and fluorescein scores (P<0.005).
Significant improvements were observed also in rose bengal
staining and tear break-up time. In 7 of 14 patients, the respon-
ses were maintained for 6 to 41 months, while 6 of the other 7
patients required treatment with punctal plugs in addition to
autologous serum eye drops.
Refractive surgery
One of the most common complications of photorefrac-
tive keratectomy (PRK) and laser in situ keratomileusis
(LASIK) is dry eye syndrome. Although dry eye after refrac-
tive surgery is usually transient, some patients complain of
severe symptoms, which may negatively influence their sa-
tisfaction with the outcome of the procedure(30). Both kera-
torefractive procedures have been reported to perturb the
ocular surface homeostasis by causing a decrease in corneal
sensitivity(31), tear film instability, decreased aqueous tear
production, and corneal and conjunctival epitheliopathy(30).
Noda-Tsuruya et al.(32) evaluated the efficacy of 20%
autologous serum eye drops for dry eye after LASIK. Fifty-
four eyes that underwent LASIK were divided into two groups;
patients who used autologous serum eye drops and those who
used artificial tears postoperatively. The results showed that
break-up time test and vital staining were significantly im-
proved in the autologous serum eye drops group, whereas no
change was reported in the artificial tear group at 6 months
postoperatively. These findings suggest that autologous se-
rum eye drops could be effective for postoperative dry eye
induced by LASIK.
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Toda et al.(33) performed LASIK in three patients who
suffered from Sjögren’s syndrome and showed decreased reflex
tearing. They inserted punctal plugs and prepared the 20%
autologous serum at the first visit of each patient. The proce-
dure was scheduled to be undertaken after the ocular surface
damage was healed by the treatment. LASIK was then perfor-
med uneventfully, and no complications were observed in any
of the patients. These results indicate that LASIK may be safely
performed on patients with severe dry eye, if the ocular surface
damage is aggressively treated before surgery.
Aniridic keratopathy
Keratopathy occurs in 20% to 90% of patients with
aniridia and is caused by a primary dysfunction of the limbal
stem cells. Corneal changes include recurrent erosions and
ulcerations of corneal epithelium, tear film instability, dry
eye, chronic pain, corneal vascularization, progressive cor-
neal opacification, and blindness. López-García et al.(34) stu-
died the effect of 20% autologous serum eye drops in a
prospective case series of 26 eyes of 13 patients with aniridic
keratopathy. The mean age of the patients was 26 ± 9.5 years
(range 9 to 48 years). There were no local side effects from
autologous serum treatment, and all patients showed a sub-
jective improvement of keratopathy symptoms after the
serum application. The corneal reepithelialization, corneal
epithelial cell squamous metaplasia, and tear stability impro-
ved significantly with the treatment, but visual acuity, re-
gression of vascular pannus, and subepithelial scarring sho-
wed only slight improvement.
Ocular surface reconstruction
Ocular cicatricial pemphigoid and Stevens-Johnson syn-
drome are severe ocular surface diseases of unknown origin
that often result in bilateral blindness, despite such treatment
as immunosuppression. Although penetrating keratoplasty is
an established procedure for the accompanying conditions,
including severe dry eye, lack of corneal stem cells, trichiasis,
and persistent ocular surface inflammation, make these di-
seases refractory to treatment. Tsubota et al.(35) evaluated 14
eyes of 11 patients with cicatricial keratoconjunctivitis (7
patients with cicatricial pemphigoid and 4 with Stevens-
Johnson syndrome). The patients were treated with a combina-
tion of allograft limbal transplantation, amniotic membrane
transplantation, and tarsorrhaphy, followed every 15 minutes
by 20% autologous serum eye drops. Eight patients required
concomitant penetrating or lamellar keratoplasty because of
corneal opacity. With a mean follow-up of 143 days (range 10
to 608 days), the authors achieved successful ocular surface
reconstruction in 12 eyes (86%), with minimal recurrence of
symblepharon. However, failure occurred in 2 eyes that de-
veloped corneal infiltrations and vascularization.
Mooren’s ulcer
Mooren’s ulcer is an uncommon, inflammatory kerato-
pathy characterized by severe pain, conjunctival and episcle-
ral injection, and peripheral corneal ulceration. The corneal
changes may expand centrally or peripherally producing
dramatic corneal thinning, often with an overhanging edge
of superficial cornea. One or both eyes may be affected and
recurrences are common. Most cases resolve with stromal
thinning and scarring, although a minority of cases advance
to perforation. Its clinical course and eventual prognosis is
variable and usually these ulcers respond poorly to conven-
tional therapy. Mavrakanas et al.(36) reported a case of Moo-
ren’s ulcer treated with antibiotic, corticosteroid and cy-
closporine therapy. The patient did not respond well to
initial treatment, but reepithelialization occurred and the
corneal deficit improved after the introduction of 20% auto-
logous serum eye drops. Therefore, autologous serum ap-
pears to be an effective supplementary treatment in Moo-
ren’s ulcer, by providing enhanced conditions for epithelial
healing and by modulating the corneal inflammatory and
immune response.
Stability, drawbacks, potential risks, complications, and
patient information
Stability
Regarding stability, Tsubota et al.(7) reported that the
concentration of growth factors, vitamin A, and fibronectin
in 100% and 20% serum diluted with NaCl stored at +4°C
remained unchanged for 1 month and at -20°C for at least 3
months. However, no more detailed published evidence is
available to clarify the minimum freezer temperature re-
quired for several months of storage. Leite et al.(37) analyzed
viability of autologous serum by the presence of insulin and
protein levels. The authors found insulin levels in autolo-
gous serum of 2.30 ± 0.60 (n= 9) at day 0 and 1.60 ± 0.70 ng/ml
(n=5) at day 30 (P=0.84). The protein levels were 51.10 ± 2.70
at day 0 (n=9) and 50.70 ± 4.60 ng/ml at day 30 (n=5)
(P=0.47).
Drawbacks of serum eye drops treatment
Since autologous serum preparation is a body fluid, it is
able to transmit infections(2). Another drawback of autolo-
gous serum treatment lies in the frequent blood extractions,
mainly in the groups requiring prolonged treatment. In these
cases, it is important to pay attention because not all patients
can be treated due to systemic difficulties and in some occa-
sions it is even necessary to provide an iron sulphate supple-
ment to prevent anemia(5). Autologous serum contains no
preservatives, which avoids the risk of preservative toxicity,
however, there is a potential risk of inducing infections
because of microbial contamination of the dropper bottle(16).
Leite et al.(37) analyzed 11 autologous serum samples after 30
days of use by the patients, in which 6 of them were conta-
minated by single or multiple microorganisms such as: Kleb-
siella pneumoniae (4/6), Streptococcus viridans (3/6), Candi-
da sp (1/6), Pseudomonas aeruginosa (1/6), Bacillus sp (1/6),
Staphylococcus aureus (1/6), Micrococcus sp (1/6).
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Complications
The literature describes some complications such as the
deposit of immunoglobulins in the cornea and the presence
of corneal peripheral infiltrates with 100% autologous serum
treatment in one patient(38). The literature does not describe
either side effect when utilized for long periods of time.
Autologous serum treatment is usually well tolerated and
most patients report improvement of discomfort sensation.
Although uncommon, some patients may experience increa-
sed discomfort, slight epitheliopathy, bacterial conjunctivi-
tis or eyelid eczema, according to some reports(5).
Standardizing the production of serum eye drops
Neither production nor application of serum have been
standardized so far. It also remains unclear whether the serum
should be filter-sterilized to remove any corpuscular blood
components. The variable efficacy of serum eye drops sug-
gests that the parameters for their production should be stan-
dardized and optimized before any meaningful placebo
controlled randomized clinical trial can evaluate the real
potential of this therapy(2).
Quality control and patient information
The use of autologous serum requires proper preparation
of the serum formulation with adequate informed consent and
education of the patient. The patient should be informed of
the risks of infection and the need to maintain the vials
properly refrigerated to minimize contamination.
In case of homologous use and to reduce the risk of infection
from diseases transmitted through blood, it is strongly recom-
mended that the donor be tested for blood-transmitted diseases
such as HIV, hepatitis B virus, hepatitis C virus, and syphilis(39).
Bacterial contamination is a potential risk in the production and
use of serum eye drops. Sterile manufacturing conditions, begin-
ning with thorough skin disinfection, are very important. A
microbiological examination of the product should be perfor-
med before application in order to rule out bacterial contamina-
tion resulting from the production process(2).
CONCLUSIONS
Treatment with autologous serum is an efficient method
to provide a number of growth factors that have been reduced
by ocular surface disorders. There is some medical evidence
that autologous serum might be clinically effective in some
particular ocular surface diseases compared to standard
treatment. Moreover, both treatments can supplement each
other, thus reducing artificial tear dependency.
RESUMO
O soro autólogo tem sido adotado como uma nova abor-
dagem para tratar síndrome do olho seco porque contém
vitaminas, alguns fatores de crecimento e fibronectina que
são considerados importantes contribuintes para integridade
corneana e conjuntival. Colírio de soro autólogo é produzido
sem preservativo. O soro é não-alérgico e suas propriedades
bioquímicas são similares à lágrima. O soro autólogo tópico
tem sido relatado efetivo para o tratamento de olho seco grave
relacionado a distúrbios da superfície ocular como na síndro-
me de Sjögren, ceratoconjuntivite límbica superior, doença
do enxerto versus hospedeiro, síndrome de Stevens-Johnson,
procedimentos cerato-refrativos, erosão corneana persistente
ou recorrente, ceratopatia neurotrófica, úlcera de Mooren,
ceratopatia associada à aniridia, e bolhas filtrantes após tra-
beculectomia. O objetivo do presente estudo é revisar a lite-
ratura recentemente publicada sobre doenças da superficie
ocular tratadas com soro autológo tópico.
Descritores: Doenças da córnea/terapia; Doenças da conjun-
tiva/terapia; Aparelho lacrimal/anormalidades; Soro; Solu-
ções oftálmicas/uso terapêutico
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